Labcorp Expands MRD Testing Portfolio to Enhance Early Cancer Recurrence Detection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Source: PRnewswire
- Portfolio Expansion: Labcorp has launched Labcorp Plasma Detect ID and Labcorp Plasma Detect Genome MRD tests aimed at helping clinicians detect cancer recurrence earlier, particularly for stage I-III breast cancer and stage III colon cancer patients, enhancing the precision of cancer monitoring.
- Recurrence Risk Data: Approximately 35% of stage III colon cancer patients experience recurrence post-treatment, while 10% to 40% of stage I-III breast cancer patients face similar risks, highlighting the critical role of MRD testing in post-treatment monitoring, providing alerts months before clinical relapse.
- Enhanced Detection Sensitivity: Labcorp's MRD tests can detect circulating tumor DNA (ctDNA) down to 0.005%, making tumor monitoring more sensitive and enabling oncologists to tailor personalized surveillance strategies, thereby increasing patient confidence in their treatment journey.
- Clinical Research Support: The MRD testing products from Labcorp have been validated in several clinical studies, particularly in patients with diffuse pleural mesothelioma and head and neck cancer, further establishing the essential role of MRD testing in personalized cancer care and advancing precision medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 304.45 USD with a low forecast of 270.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 268.040
Low
270.00
Averages
304.45
High
325.00
Current: 268.040
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Holdings Inc. to Release Q4 2025 Financial Results on February 17, 2026
- Earnings Release Schedule: Labcorp will release its Q4 2025 financial results before the market opens on February 17, 2026, expected to provide key financial metrics and business performance insights for investors to assess market standing.
- Conference Call Details: The company will host a conference call and webcast at 9 a.m. ET on the same day to discuss the financial results, enhancing transparency and engaging with investors directly.
- Investor Relations Website: The earnings press release and accompanying financial information will be posted on Labcorp's Investor Relations website, ensuring timely access to the latest information for all stakeholders and improving information accessibility.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event and will remain accessible until February 4, 2027, ensuring that investors who cannot participate live can still obtain important information.
Continue Reading
UniFirst Declares $0.365 Dividend, Kaiser Aluminum Announces $0.77 Dividend
- UniFirst Dividend Announcement: UniFirst's Board of Directors declared a quarterly cash dividend of $0.365 per share, payable on March 27, 2026, reflecting the company's ongoing profitability and commitment to shareholder returns.
- Kaiser Aluminum Dividend Declaration: Kaiser Aluminum announced a cash dividend of $0.77 per share, payable on February 13, 2026, demonstrating the company's strong performance in maintaining stable cash flow and shareholder returns.
- Agree Realty Dividend Increase: Agree Realty declared a monthly cash dividend of $0.262, with an annualized amount rising to $3.144, a 3.6% increase from Q1 2025, showcasing the company's focus on shareholder value and confidence in profit growth.
- Labcorp Dividend Payment: Labcorp Holdings announced a cash dividend of $0.72 per share, payable on March 12, 2026, indicating its robust financial performance in the innovative laboratory services sector.
Continue Reading